Cargando…

COVID-19 in rheumatic disease patients on immunosuppressive agents

OBJECTIVE: To analyze clinical characteristics and outcome of COVID-19 patients with underlying rheumatic diseases (RD) on immunosuppressive agents. METHOD: A case series of COVID-19 patients with RD on disease modifying anti-rheumatic drugs (DMARDs) were studied by a retrospective chart review. A l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharmeen, Saika, Elghawy, Ahmed, Zarlasht, Fnu, Yao, Qingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245236/ https://www.ncbi.nlm.nih.gov/pubmed/32512263 http://dx.doi.org/10.1016/j.semarthrit.2020.05.010

Ejemplares similares

Current State of Platelet-rich Plasma in the Treatment of Rheumatic Disease: A Retrospective Review of the Literature
por: Jacobs, Adam, et al.
Publicado: (2023)

A Case of Recurrent Pasteurella Bacteremia in an Immunocompetent Patient with No Animal Bite
por: Zarlasht, Fnu, et al.
Publicado: (2018)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination
por: Barbhaiya, Medha, et al.
Publicado: (2022)

The protective effect of rheumatic disease agents in COVID-19
por: Valenzuela-Almada, María O., et al.
Publicado: (2021)

COVID-19 antiviral therapy for non-hospitalized immunosuppressed patients with rheumatic diseases is feasible with positive outcomes
por: Lin, Chung M A, et al.
Publicado: (2022)

Encephalitis treatment – a case report with long-term follow-up of EBV PCR in cerebrospinal fluid
por: Zarlasht, Fnu, et al.
Publicado: (2017)

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021)

Inpatient Rheumatology Consultation Prompted by Positive Autoantibodies in Patients Receiving Intravenous Immunoglobulin Therapy: A Case Series and Literature Review
por: Fnu, Zarlasht, et al.
Publicado: (2023)

Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey
por: Dahm, Simon, et al.
Publicado: (2023)

SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy
por: Lledó, Ana, et al.
Publicado: (2021)

Short-Term High-Dose Steroid Therapy in a Case of Rhabdomyolysis Refractory to Intravenous Fluids
por: Zarlasht, Fnu, et al.
Publicado: (2017)

A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases
por: Patil, Abhishek, et al.
Publicado: (2022)

Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum
por: Louapre, C., et al.
Publicado: (2020)

An Unusual Case of Systemic Lupus Erythematosus and Hemophagocytic Syndrome
por: Sharmeen, Saika, et al.
Publicado: (2016)

Is it safe to vaccinate rheumatic immunosuppressed patients? Yes, of course, but how?
por: Gillet, Pierre
Publicado: (2021)

Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease
por: Frommert, Leonie Maria, et al.
Publicado: (2022)

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
por: Sugihara, Koichi, et al.
Publicado: (2022)

Rheumatic Disease Patients with COVID-19 Diagnosis
por: Treadwell, Edward L.
Publicado: (2020)

The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence
por: Zhang, Mengyuan, et al.
Publicado: (2021)

Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases
por: Alzahrani, Zeyad A., et al.
Publicado: (2021)

Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea
por: Lee, Sang Yeob, et al.
Publicado: (2011)

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments
por: Ouédraogo, Dieu-Donné, et al.
Publicado: (2020)

Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19
por: Koker, Oya, et al.
Publicado: (2020)

Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study
por: Rotondo, Cinzia, et al.
Publicado: (2021)

Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
por: Yousefghahari, Behnaz, et al.
Publicado: (2021)

ANCA-Associated Necrotizing Glomerulonephritis Overlapping with Mesangial Proliferative Lupus Nephritis Refractory to Plasmapheresis, Steroid Pulse Therapy, and a Combination of Mycophenolate Mofetil and Rituximab
por: Sharmeen, Saika, et al.
Publicado: (2018)

Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic
por: Ganjei, Zakiye, et al.
Publicado: (2021)

Cytomegalovirus Pneumonia in Patients with Rheumatic Diseases After Immunosuppressive Therapy: A Single Center Study in China
por: Xue, Yu, et al.
Publicado: (2016)

Pharmacological immunosuppressive agents.
por: Salaman, J. R.
Publicado: (1981)

COVID-19 – rheumatic diseases and rheumatologists
por: Maślińska, Maria
Publicado: (2021)

Assessment of symptoms of the post-COVID-19 syndrome in patients with different rheumatic diseases
por: Ismail, Zahraa Nour Eldine, et al.
Publicado: (2023)

Digestive Agents in Inflammatory Rheumatism
por: Swentningen, S. V.
Publicado: (1881)

Evolution of COVID-19 in patients with autoimmune rheumatic diseases
por: Pang, Rongrong, et al.
Publicado: (2020)

COVID-19 Among Patients With Inflammatory Rheumatic Diseases
por: Esatoglu, Sinem Nihal, et al.
Publicado: (2021)

COVID-19 breakthrough infections in rheumatic diseases patients after vaccination
por: Alshukairi, Abeer N., et al.
Publicado: (2022)

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
por: Marques, Claudia Diniz Lopes, et al.
Publicado: (2021)

Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
por: Kraus, Courtney L., et al.
Publicado: (2012)

Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
por: Perricone, Carlo, et al.
Publicado: (2020)

Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents
por: Costagliola, Giorgio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fu6sgcvp26s9tcvb4dtl4r4bsv